Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

d LV with oxaliplatin) after three months of therapy or sooner if significant (Grade 3 or greater) neurotoxicity develops. For more information, please see http://www.nccn.org.

In the Phase 1 study, 50 patients were treated with picoplatin on either an every-two-week or an every-four-week basis in combination with the standard of care every-two-week dose of 5FU and LV. Patients received up to 28 cycles, and the therapy was well tolerated. Increased hematological toxicity was observed at higher doses. None of the patients treated with picoplatin exhibited a Grade 3 or higher neuropathy and only 9 of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of Grade 2 or greater was observed in the 26 patients who received greater than or equal to 400 mg/m squared picoplatin. Mild nephro- and oto- toxicity were observed infrequently. The dose limiting toxicity (DLT) was most frequently hematological with neutropenia and thrombocytopenia. The maximum tolerated dose was established in the every-four-week schedule at 150 mg/m squared. The maximum tolerated dose for the every-two-week schedule has not yet been reached.

Based on the evidence of a more attractive safety profile of picoplatin in this combination (FOLPI) compared to the standard of care regimen with oxaliplatin (FOLFOX) as well as clinical activity in the Phase 1 study, the Company initiated a randomized Phase 2 trial in November, 2007 to evaluate intravenous picoplatin in the first-line treatment of mCRC. The Phase 2 trial is intended to generate proof-of-concept data to further evaluate efficacy and safety, including neuropathy of picoplatin in combination with 5-FU and LV (FOLPI versus FOLFOX) and to provide support for a potential registrational Phase 3 trial. The Company expects to present data from the Phase 1 and 2 mCRC program in scientific forums around mid year.

About Picoplatin

Picoplatin is an intravenous chemoth
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 According to a ... of Material, Application (Healthcare, Homeland security, Industrial application, ... Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) & ... published by MarketsandMarkets, the Scintillator Market is expected ... 2014 to 2020, and reach $479.16 Million in ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... , NEW YORK, ... market research report is available in its catalogue: ... Pharmaceuticals - Current and Future Market Outlook, Regulatory ... , Summary , The author ...
... , NEWNAN, ... specialty surface treatments for medical devices and of specialty implants, ... Gordy, will give an opening address for the Technology Parade ... Israel. "We must leave the era of petty self-interest ...
Cached Medicine Technology:Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2
(Date:7/14/2014)... (PRWEB) July 14, 2014 The governments ... investment in the Global Mobile Health Solutions market. For ... the Health IT for Economic and Clinical Health Act ... 2009. , Analysts forecast the Global Mobile Health ... 34.88 percent over the period 2013-2018. According to the ...
(Date:7/14/2014)... July 14, 2014 The report ... Services [Physical Security, Life Safety, Facility Management], IT ... Forecast & Analysis (2014 - 2019)” defines and ... an in-depth analysis and forecasting of revenues. The ... various restraints and opportunities impacting it, along with ...
(Date:7/14/2014)... fitness may buffer some of the adverse health effects ... by researchers from the American Cancer Society, The Cooper ... in the journal Mayo Clinic Proceeding s, and ... and blood markers associated with cardiovascular disease is markedly ... behavior has been linked to an increase risk of ...
(Date:7/14/2014)... 14, 2014 This report provides ... in Americas. The analysis includes market size data ... and key company share data by revenue in ... and Mexico. It uses data and information sourced ... in-house analysis. , Scope,     Information ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... and Willing to ... 20s, - Boomers Can Stay On-the-Go with New ThermaCare(R) Arthritis HeatWraps ... percent of baby boomers claim they feel an average of 11 ... they are more,adventurous and willing to experiment now than when they ...
... guided trial design may increase probability of tumor response ... and accelerates ... (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... to its complete phase Ib trial of brostallicin used in ...
... CARLSBAD, Calif., Oct. 18 Isis,Pharmaceuticals, Inc. (Nasdaq: ... added a,new diabetes drug targeting the sodium dependent ... ISIS 388626, a generation 2.2,antisense drug that acts ... existing pipeline of drugs in development for the,treatment ...
... Lighted slippers for,those with troubled eyesight. A ... the player,s motions. Bowling equipment for those with ... One-stop online shopping for older adults and ... easier at Rehability! Your Optimal Living,Store, http://www.rehabilitystores.com ...
... Oct. 18 More than half of holiday shoppers ... to a good cause*. This,year, choose a gift that ... Alzheimer,s disease, the seventh leading cause of death,in the ... services for families struggling with,Alzheimer,s or support innovative research ...
... at US$26.00 Per Share -, VICTORIA, Oct. ... ; TSX: ASV) today announced that it has ... GALN) under which,Galenica, through a wholly-owned Canadian subsidiary, ... price of US$26.00 per share in cash. The,total ...
Cached Medicine News:Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 3Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 4Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 2Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 3Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 4Health News:Holiday Gifts for Those With Disabilities & Other Special Needs 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 3Health News:Aspreva to be Acquired by Galenica For US$915 Million 4Health News:Aspreva to be Acquired by Galenica For US$915 Million 5
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... ThumbFit™ reduces joint instability without disturbing ... remarkably comfortable and easy for users ... CHT and Robert V. Sypher Jr., ... in response to patients' complaints of ...
... the MP joint and the CMC joint of the ... both of the thumb joints. An excellent choice for ... who need maximum mobility for daily activities. Ideal for ... and for those with pain due to repetitive stress. ...
... molded from rigid plastic in a distinctive design ... comfort. The uniquely sculpted distal trim line ... maximum function of the hand. This is ... and sprains of the MCP joint, basal joint ...
Medicine Products: